The inflammatory T cell phenotype seen in Selplg−/− mice provides support for the therapeutic targeting of PSGL-1 on CD4+ T cells in cancer, as it may provide a way to lessen immune suppression and increase the activation of T cells. This evidence concerns the gene CD4 and cancer.